UK Markets open in 2 hrs 51 mins
  • NIKKEI 225

    29,262.44
    +236.98 (+0.82%)
     
  • HANG SENG

    25,706.50
    +296.75 (+1.17%)
     
  • GOLD FUTURES

    1,775.30
    +9.60 (+0.54%)
     
  • DOW

    35,258.61
    -36.15 (-0.10%)
     
  • BTC-GBP

    45,447.97
    +100.50 (+0.22%)
     
  • CMC Crypto 200

    1,463.76
    +12.12 (+0.84%)
     
  • Nasdaq

    15,021.81
    +124.47 (+0.84%)
     
  • ^FTAS

    4,110.17
    -13.80 (-0.33%)
     

Worldwide Polymerase Chain Reaction Industry to 2028 - by Type, Product, Application and Region

·9-min read

Dublin, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The "Polymerase Chain Reaction Market Size, Share & Trends Analysis Report By Type, By Product (Instruments, Consumables & Reagents), By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global polymerase chain reaction market size is expected to reach USD 25.3 billion by 2028, according to a new report by the publisher. The market is estimated to expand at a CAGR of 0.9% from 2021 to 2028. This is driven by an increase in demand for rapid diagnostic tests and technological advancements.

Key players operating in the market are focusing on introducing novel and technologically advanced devices for PCR tests. For instance, in July 2017, Bio-Rad Laboratories launched droplet digital PCR Genome Edit Detection Assays to quantify the efficiency of CRISPR-Cas9 or any other genome using the technology of Bio-Rad's droplet digital polymerase chain reaction. This technology has gained prominence over the past few years.

Furthermore, the COVID-19 outbreak has increased the growth rate of dPCR technology. Several types of research activities are being conducted for proving the accuracy of the dPCR test. For instance, in March 2020, researchers of the Center for Advanced Measurement Science worked with Chongqing University in collaboration with the Centers for Disease Prevention and Control of Wuhan and Beijing for detecting the sensitivity of dPCR kits. In addition, two more studies were conducted in China that suggested improved sensitivity as compared to gold standard RT-qPCR. Moreover, in March 2020, Bio-Rad Laboratories developed a dPCR test for the detection of the SARS-CoV-2 virus.

Various research initiatives being undertaken coupled with increasing collaborations between companies for the development of tests are factors anticipated to drive the growth of the segment. In May 2020, Xiamen University, in collaboration with the Chinese University of Hong Kong and University of Connecticut, was engaged in the development of an experimental procedure for developing and validating a qPCR assay for the detection of Symbiodiniaceae genera. Furthermore, sxtA-based qPCR tests were proved to be effective against Alexandrium catenella in 2019.

Government initiatives undertaken to boost testing capacity are expected to drive the market. For instance, in September 2020, the National Institutes of Health offered USD 129.3 million under the Rapid Acceleration of Diagnostics (RADx) initiative to drive manufacturing and usage of RT-PCR. The growing number of tests conducted by governments to counter the COVID-19 pandemic is expected to act as a driver for qPCR and dPCR market. For instance, Iceland has conducted 135 tests per 1,000 population.

The introduction of novel PCR such as plasmonic PCR in the PoC diagnostics platform is expected to be a disruptive technology, as existing PCR platforms are slow, expensive, and energy costly. Therefore, the development of lower-cost PoC technology with high accuracy is expected to reduce the procurement cost for medical use and overall laboratory cost of a patient in countries of Asia Pacific, North America, and Europe.

Moreover, initiatives are undertaken by key players to enhance their product portfolios and global presence. For instance, in September 2020, Qiagen acquired NeuMoDx Molecular, Inc. for USD 248 million. The acquisition is anticipated to boost Qiagen's PCR portfolio and enhance its global presence as well as customer access.

Polymerase Chain Reaction Market Report Highlights

  • In 2020, the others type segment which includes real-time PCR (qPCR), digital PCR (dPCR), multiplex, and ultrafast PCR held a majority of the share. Increasing demand and high adoption due to its ability to detect pathogens and infection rapidly, automation, and cost-effective are factors supporting segment growth

  • The consumables and reagents segment dominated the market in 2020 owing to increased demand for consumables and reagents to meet the heightened testing demands during the pandemic

  • The medical segment held the largest revenue share in 2020 due to an increase in clinical testing along with rising research activities for DNA cloning, microbiome analysis, and gene expression

  • In Asia Pacific, the market is projected to witness the fastest growth during the forecast period owing to high-unmet needs and improving healthcare infrastructure

  • North America dominated the market in 2020 due to the presence of key players and rising initiatives to raise awareness among healthcare professionals and patients

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 PCR Market - Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rising incidence of chronic diseases, infectious diseases, and genetic disorders
3.3.1.2 Technological advancements in PCR
3.3.1.3 Implementation of MIQE guidelines
3.3.1.4 Increasing demand for rapid diagnostic tests and growing adoption of PCR technologies
3.3.1.5 Increasing number of CROs and forensic & research laboratories
3.3.1.6 Increasing demand for prenatal genetic testing procedures
3.3.1.7 Outbreak of COVID-19
3.3.2 Market restraint Analysis
3.3.2.1 High qPCR device costs
3.3.2.2 Stringent regulatory policies
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter's
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances

Chapter 4 PCR Market Analysis: Type Scope, 2017 - 2028 (Revenue, USD Million)
4.1 PCR Market: Type Movement Analysis
4.2 Conventional PCR
4.2.1 Conventional PCR market estimates and forecast, 2017 - 2028 (USD million)
4.3 Others
4.3.1 Others market estimates and forecast, 2017 - 2028 (USD million)

Chapter 5 PCR Market Analysis: Product Scope, 2017 - 2028 (Revenue, USD Million)
5.1 PCR Market: Products Movement Analysis
5.2 Consumables & Reagents
5.2.1 Consumables & reagents market estimates and forecast, 2017 - 2028 (USD Million)
5.3 Instruments
5.3.1 Instruments market estimates and forecast, 2017 - 2028 (USD Million)
5.4 Software & Services
5.4.1 Software & services market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 6 PCR Market Analysis: Application Scope, 2017 - 2028 (Revenue, USD Million)
6.1 PCR Market: Application Movement Analysis
6.2 Medical
6.2.1 Medical market estimates and forecast, 2017 - 2028 (USD million)
6.2.2 Clinical
6.2.3 Clinical market estimates and forecast, 2017 - 2028 (USD million)
6.2.3.1 Pathogen Testing
6.2.3.1.1 Pathogen testing market estimates and forecast, 2017 - 2028 (USD million)
6.2.3.2 Oncology Testing
6.2.3.2.1 Oncology testing market estimates and forecast, 2017 - 2028 (USD million)
6.2.3.3 Blood Screening
6.2.3.3.1 Blood screening market estimates and forecast, 2017 - 2028 (USD million)
6.2.3.4 Others
6.2.3.4.1 Others market estimates and forecast, 2017 - 2028 (USD million)
6.2.4 Research
6.2.4.1 Research market estimates and forecast, 2017 - 2028 (USD million)
6.2.5 Forensics and Others
6.2.5.1 Forensics and others market estimates and forecast, 2017 - 2028 (USD million)
6.3 Non-medical
6.3.1 Non-medical market estimates and forecast, 2017 - 2028 (USD million)
6.3.2 Food
6.3.2.1 Food market estimates and forecast, 2017 - 2028 (USD million)
6.3.3 Others
6.3.3.1 Others market estimates and forecast, 2017 - 2028 (USD million)

Chapter 7 PCR Market Analysis, Regional Scope, 2017 - 2028, (Revenue, USD Million)

Chapter 8 PCR Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix`
8.2 Company Categorization
8.2.1 Innovators
8.2.1.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.3.3 Key company market share analysis, 2020
8.4 Public Companies
8.4.1 Competitive dashboard analysis
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Regional Network Map
8.7 Key Regional/Local Competitors for PCR Consumables/Enzymes in Japan, Australia, Korea, India, Singapore, and Europe
8.8 Company Profiles
8.8.1 Abbott
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 Qiagen
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 Bio-Rad Laboratories, Inc.
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 Agilent Technologies, Inc.
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 Thermo Fisher Scientific, Inc.
8.8.5.1 Company overview
8.8.5.2 Affymetrix
8.8.5.3 Company overview
8.8.5.4 Financial performance
8.8.5.5 Product benchmarking
8.8.5.6 Strategic initiatives
8.8.6 Cytiva (GE Healthcare)
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 bioMerieux SA
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 F. Hoffmann-La Roche Ltd.
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives
8.8.9 Fluidigm Corporation
8.8.9.1 Company overview
8.8.9.2 Financial performance
8.8.9.3 Product benchmarking
8.8.9.4 Strategic initiatives
8.8.10 STILLA
8.8.10.1 COMPANY OVERVIEW
8.8.10.2 Product benchmarking
8.8.10.3 Strategic initiatives
8.8.11 Microsynth AG
8.8.11.1 Company overview
8.8.11.2 Product benchmarking
8.8.11.3 Strategic initiatives
8.8.12 JN Medsys
8.8.12.1 Company overview
8.8.12.2 Product benchmarking
8.8.12.3 Strategic initiatives
8.8.13 Danaher Corporation
8.8.13.1 Company overview
8.8.13.2 Cepheid
8.8.13.3 Beckman Coulter
8.8.13.4 Leica Biosystems
8.8.13.5 Financial performance
8.8.13.6 Product benchmarking
8.8.13.7 Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/70pgrq

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting